Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00127101
Status:
TERMINATED
Last Update Posted:
2015-04-21
First Post:
2005-08-02
Brief Title:
An Investigational Study of a Histone Deacetylase HDAC Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients 0683-016TERMINATED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid Vorinostat Zolinza in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma
Status:
TERMINATED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was stopped due to low enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an investigational study that increases the dosage to determine the safetytolerability and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients who have failed at least one prior systemic therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_019 | None | None | None |
| MK0683-016 | None | None | None |